Ongoing Clinical Trials for Primary Mediastinal Large B-Cell Lymphoma Refractory
Currently, there is 1 ongoing clinical trial investigating treatment options for primary mediastinal large B-cell lymphoma that has not responded to previous therapies. This trial is evaluating pembrolizumab, an immunotherapy medication, and is being conducted across multiple European countries including Italy, Poland, and Czechia.
Clinical trial locations
- Czechia
- Italy
- Poland
Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma or Primary Mediastinal Large B-cell Lymphoma
This clinical trial is investigating pembrolizumab as a treatment option for patients whose disease has either returned after previous treatment or has not responded to earlier therapies. The study focuses on two types of lymphoma, including primary mediastinal large B-cell lymphoma.
Who can participate:
- Patients with a confirmed diagnosis of primary mediastinal large B-cell lymphoma that is either relapsed (has returned) or refractory (has not responded to treatment)
- The disease must be measurable on imaging tests, with at least one lymph node larger than 15 mm in one direction that has not been treated with radiation, or a tumor outside the lymph nodes larger than 10 mm in both directions
- Patients must have experienced a relapse after undergoing a stem cell transplant
- Both male and female adults within the specified age range can participate
Who cannot participate:
- Patients who have not experienced a return or worsening of their condition after previous treatment
- Individuals who do not fall within the specified age range for the study
- Participants who belong to vulnerable populations, such as those unable to give informed consent
What the trial involves:
The study is evaluating pembrolizumab, also known by its code name MK-3475. This medication is an immune checkpoint inhibitor, which means it works by helping the body’s immune system recognize and attack cancer cells more effectively. It blocks a specific protein on immune cells, enhancing the natural defense system to fight the disease.
Pembrolizumab is given as an intravenous infusion directly into the bloodstream through a vein. The treatment is administered every six weeks at a dosage of 25 mg/mL. Participants will undergo regular check-ups and imaging tests throughout the study to monitor how well the treatment is working and to assess any side effects.
The trial follows a structured approach. First, an initial assessment confirms the diagnosis and ensures the disease meets specific criteria. Then, treatment begins with regular pembrolizumab infusions. Throughout the study, doctors will monitor the response using specific assessment criteria to evaluate the objective response rate and measure how long the response lasts. The study is expected to continue until the end of 2025, when final assessments will be conducted to gather data on the effectiveness and safety of the treatment.
Summary
Currently, there is one active clinical trial available for patients with refractory primary mediastinal large B-cell lymphoma. This trial is being conducted in three European countries: Italy, Poland, and Czechia, providing access to patients across Central and Southern Europe. The study focuses exclusively on pembrolizumab, an immunotherapy medication that works by enhancing the body’s immune response against cancer cells. This trial is particularly relevant for patients who have already undergone stem cell transplantation but have experienced disease relapse, representing an important option for those with limited treatment alternatives.
